Andrey Poloznikov

Dr. Andrey Poloznikov

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2020 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
TGTatiana Gerasimenko
Tatiana Gerasimenko
SNSergey Nikulin
Sergey Nikulin
GZGalina Zakharova
Galina Zakharova
APAndrey Poloznikov
Andrey Poloznikov
VPVladimir Petrov
Vladimir Petrov
ATAlexander Tonevitsky
Alexander Tonevitsky
In contrast to traditional 2D cell cultures, both 3D models and organ-on-a-chip devices allow the study of the physiological responses of human cells. These models reconstruct human tissues in conditions closely resembling the body. Translation of these techniques into practice is hindered by associated labor costs, a need which may be remedied by automation. Impedance spectroscopy (IS) is a promising, automation-compatible label-free technology allowing to carry out a wide range of measurements both in real-time and as endpoints. IS has been applied to both the barrier cultures and the 3D constructs. Here we provide an overview of the impedance-based analysis in different setups and discuss its utility for organ-on-a-chip devices. Most attractive features of impedance-based assays are their compatibility with high-throughput format and supports for the measurements in real time with high temporal resolution, which allow tracing of the kinetics. As of now, IS-based techniques are not free of limitations, including imperfect understanding of the parameters that have their effects on the impedance, especially in 3D cell models, and relatively high cost of the consumables. Moreover, as the theory of IS stems from electromagnetic theory and is quite complex, work on popularization and explanation of the method for experimental biologists is required. It is expected that overcoming these limitations will lead to eventual establishing IS based systems as a standard for automated management of cell-based experiments in both academic and industry environments.

5 November 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MAManuj Ahuja
Manuj Ahuja
NKNavneet Ammal Kaidery
Navneet Ammal Kaidery
OAOtis C. Attucks
Otis C. Attucks
EMErin McDade
Erin McDade
DHDmitry Hushpulian
Dmitry Hushpulian
Bobby ThomasBobby Thomas
Bobby Thomas
Parkinson's disease (PD) is a progressive neurodegenerative movement disorder characterized by the loss of nigrostriatal dopaminergic neurons. Mounting evidence suggests that Nrf2 is a promising target for neuroprotective interventions in PD. However, electrophilic chemical properties of the canonical Nrf2-based drugs cause irreversible alkylation of cysteine residues on cellular proteins resulting in side effects. Bach1 is a known transcriptional repressor of the Nrf2 pathway. We report that Bach1 levels are up-regulated in PD postmortem brains and preclinical models. Bach1 knockout (KO) mice were protected against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity and associated oxidative damage and neuroinflammation. Functional genomic analysis demonstrated that the neuroprotective effects in Bach1 KO mice was due to up-regulation of Bach1-targeted pathways that are associated with both Nrf2-dependent antioxidant response element (ARE) and Nrf2-independent non-ARE genes. Using a proprietary translational technology platform, a drug library screen identified a substituted benzimidazole as a Bach1 inhibitor that was validated as a nonelectrophile. Oral administration of the Bach1 inhibitor attenuated MPTP neurotoxicity in pre- and posttreatment paradigms. Bach1 inhibitor–induced neuroprotection was associated with the up-regulation of Bach1-targeted pathways in concurrence with the results from Bach1 KO mice. Our results suggest that genetic deletion as well as pharmacologic inhibition of Bach1 by a nonelectrophilic inhibitor is a promising therapeutic approach for PD.

1 April 2018 in Biochimie
Verified
Journal Article
Closed access
AOAndrey I. Osipyants
Andrey I. Osipyants
APAndrey Poloznikov
Andrey Poloznikov
NSNatalya A. Smirnova
Natalya A. Smirnova
DHDmitry M. Hushpulian
Dmitry M. Hushpulian
AKAnna Yu. Khristichenko
Anna Yu. Khristichenko
VTVladimir I. Tishkov
Vladimir I. Tishkov

1 January 2018 in ALTEX
Verified
Journal Article
Open access
APAndrey Poloznikov
Andrey Poloznikov
Most common drug development failures originate from either bioavailability problems, or unexpected toxic effects. The culprit is often the liver, which is responsible for biotransformation of a majority of xenobiotics. Liver may be modeled using "liver on a chip" devices, which may include established cell lines, primary human cells, and stem cell-derived hepatocyte-like cells. The choice of biological material along with its processing and maintenance greatly influence both the device performance and the resultant toxicity predictions. Impediments to the development of "liver on a chip" technology include the problems with standardization of cells, limitations imposed by culturing and the necessity to develop more complicated fluidic contours. Fortunately, recent breakthroughs in the development of cell-based reporters, including ones with fluorescent label, permits monitoring of the behavior of the cells embed into the "liver on a chip" devices. Finally, a set of computational approaches has been developed to model both particular toxic response and the homeostasis of human liver as a whole; these approaches pave a way to enhance the in silico stage of assessment for a potential toxicity.

17 January 2018 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
IGIrina N. Gaisina
Irina N. Gaisina
SLSue H. Lee
Sue H. Lee
NKNavneet A. Kaidery
Navneet A. Kaidery
MAManel Ben Aissa
Manel Ben Aissa
MAManuj Ahuja
Manuj Ahuja
IGIrina G. Gazaryan
Irina G. Gazaryan